These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 39386211)

  • 1. Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma.
    Aleksandrova K; Leise J; Priesner C; Aktas M; Apel M; Assenmacher M; Bürger I; Richter A; Altefrohne P; Schubert C; Holzinger A; Barden M; Bezler V; von Bergwelt-Baildon M; Borchmann P; Goudeva L; Glienke W; Arseniev L; Esser R; Abken H; Koehl U
    Front Immunol; 2024; 15():1328368. PubMed ID: 39386211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration.
    Malakhova E; Pershin D; Kulakovskaya E; Vedmedskaia V; Fadeeva M; Lodoeva O; Sozonova T; Muzalevskii Y; Kazachenok A; Belchikov V; Shelikhova L; Molostova O; Volkov D; Maschan M
    Cytotherapy; 2024 Jun; 26(6):567-578. PubMed ID: 38493403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
    Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
    Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
    Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
    Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.
    Lock D; Mockel-Tenbrinck N; Drechsel K; Barth C; Mauer D; Schaser T; Kolbe C; Al Rawashdeh W; Brauner J; Hardt O; Pflug N; Holtick U; Borchmann P; Assenmacher M; Kaiser A
    Hum Gene Ther; 2017 Oct; 28(10):914-925. PubMed ID: 28847167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
    Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
    Front Immunol; 2019; 10():2361. PubMed ID: 31649672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.
    Jackson Z; Roe A; Sharma AA; Lopes FBTP; Talla A; Kleinsorge-Block S; Zamborsky K; Schiavone J; Manjappa S; Schauner R; Lee G; Liu R; Caimi PF; Xiong Y; Krueger W; Worden A; Kadan M; Schneider D; Orentas R; Dropulic B; Sekaly RP; de Lima M; Wald DN; Reese JS
    Front Immunol; 2020; 11():1941. PubMed ID: 32849651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.
    Castella M; Caballero-Baños M; Ortiz-Maldonado V; González-Navarro EA; Suñé G; Antoñana-Vidósola A; Boronat A; Marzal B; Millán L; Martín-Antonio B; Cid J; Lozano M; García E; Tabera J; Trias E; Perpiña U; Canals JM; Baumann T; Benítez-Ribas D; Campo E; Yagüe J; Urbano-Ispizua Á; Rives S; Delgado J; Juan M
    Front Immunol; 2020; 11():482. PubMed ID: 32528460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-T cell expansion platforms yield distinct T cell differentiation states.
    Song HW; Prochazkova M; Shao L; Traynor R; Underwood S; Black M; Fellowes V; Shi R; Pouzolles M; Chou HC; Cheuk AT; Taylor N; Jin P; Somerville RP; Stroncek DF; Khan J; Highfill SL
    Cytotherapy; 2024 Jul; 26(7):757-768. PubMed ID: 38625071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functionality and Cell Senescence of CD4/ CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy® Platform.
    Aleksandrova K; Leise J; Priesner C; Melk A; Kubaink F; Abken H; Hombach A; Aktas M; Essl M; Bürger I; Kaiser A; Rauser G; Jurk M; Goudeva L; Glienke W; Arseniev L; Esser R; Köhl U
    Transfus Med Hemother; 2019 Feb; 46(1):47-54. PubMed ID: 31244581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
    Teoh J; Brown LF
    Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.
    Gargett T; Truong NTH; Gardam B; Yu W; Ebert LM; Johnson A; Yeo ECF; Wittwer NL; Tapia Rico G; Logan J; Sivaloganathan P; Collis M; Ruszkiewicz A; Brown MP
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system.
    Zhang W; Jordan KR; Schulte B; Purev E
    Drug Des Devel Ther; 2018; 12():3343-3356. PubMed ID: 30323566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
    Palen K; Zurko J; Johnson BD; Hari P; Shah NN
    Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated, scaled, transposon-based production of CAR T cells.
    Lock D; Monjezi R; Brandes C; Bates S; Lennartz S; Teppert K; Gehrke L; Karasakalidou-Seidt R; Lukic T; Schmeer M; Schleef M; Werchau N; Eyrich M; Assenmacher M; Kaiser A; Prommersberger S; Schaser T; Hudecek M
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system.
    Khaniya A; Rad SMAH; Halpin J; Tawinwung S; McLellan A; Suppipat K; Hirankarn N
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38677881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.